Chronic obstructive pulmonary disease: Role of bacteria and guide to antibacterial selection in the older patient

Drugs and Aging

Volumn 19, Issue 10, 2002, Pages 761-775

  Murphy, Timothy F ^a,b,c,d   Sethi, Sanjay ^b,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Buffalo VAMC ^*  (United States)

^d VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTICOAGULANT AGENT; AZITHROMYCIN; CEFACLOR; CEFOTAXIME; CEFPODOXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; DOXYCYCLINE; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LORACARBEF; MACROLIDE; MAGNESIUM; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TROVAFLOXACIN; ANTIINFECTIVE AGENT;

AGED; ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; CHLAMYDOPHILA PNEUMONIAE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HEART ARRHYTHMIA; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; LIVER TOXICITY; MORAXELLA CATARRHALIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; SYMPTOM; BACTERIAL INFECTION; CLINICAL TRIAL; GERIATRIC ASSESSMENT; MICROBIOLOGY;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS; GERIATRIC ASSESSMENT; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 0036425163     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219100-00005     Document Type: Review

References (68)

1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-44
2. Burrows B. Earle RH. Course and prognosis of chronic obstructive lung disease: A prospective study of 200 patients. N Engl J Med 1969; 280: 397-404
3. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-22
4. Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274: 1852-7
5. Ball P, Harris JM, Lowson D, et al. Acute infective exacerbations of chronic bronchitis. Q J Med 1995; 88: 61-8
6. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: A state of the art review. Clin Microbiol Rev 2001; 14: 336-63
7. Hirschmann JV. Do bacteria cause exacerbations of chronic obstructive lung disease. Chest 2000; 118: 193-203
8. Murphy TF, Sethi S. Niederrnan MS. The role of bacteria in exacerbations of COPD: A constructive view. Chest 2000; 118: 204-9
9. Tager I, Speizer FE. Role of infection in chronic bronchitis. N Engl J Med 1975; 292: 563-71
10. Fagon J-Y, Chastre J, Trouillet J-L, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Respir Dis 1990; 142: 1004-8
11. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152: 1316-20
12. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498-505
13. Pela R, Marchesani F, Agostinelli C, et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: A bronchoscopic investigation. Monaldi Arch Chest Dis 1998; 53: 262-7
14. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-80
15. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-45
16. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109: 288-95
17. Sethi S, Muscarella K, Evans N, et al. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000; 118: 1557-65
18. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 1067-83
19. Musher DM, Kubitschek KR, Crennan J, et al. Pneumonia and acute febrile tracheobronchitis due to Haemophilus influenzae. Ann Intern Med 1983; 99: 444-50
20. Yi K, Sethi S, Murphy TF. Human immune response to non-typeable Haemophilus influenzae in chronic bronchitis. J Infect Dis 1997; 176: 1247-52
21. Chapman AJ, Musher DM, Jonsson S, et al. Development of bactericidal antibody during Branhamella catarrhalis infection. J Infect Dis 1985; 151: 878-82
22. Murphy TF, Kirkham C, Denardin E, et al. Analysis of antigenic structure and human immune response to outer membrane protein CD of Moraxella catarrhalis. Infect Immun 1999; 67: 4578-85
23. Bhushan R, Kirkham C, Sethi S, et al. Antigenic characterization and analysis of the human immune response to outer membrane protein E of Branhamella catarrhalis. Infect Immun 1997; 65: 2668-75
24. Bakri F, Brauer AL, Sethi S, et al. Systemic and mucosal antibody response to Moraxella catarrhalis following exacerbations of chronic obstructive pulmonary disease. J Infect Dis 2002; 185: 632-40
25. Lieberman D, Lieberman D, Ben-Yaakov M, et al. Infectious etiologies in acute exacerbation of COPD. Diagn Microbiol Infect Dis 2001; 40: 95-102
26. Smith CB, Golden C, Klauber MR, et al. Interactions between viruses and bacteria in patients with chronic bronchitis. J Infect Dis 1976; 134: 552-61
27. Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976; 113: 465-73
28. McHardy VU, Inglis JM, Calder MA, et al. A study of infective and other factors in exacerbations of chronic bronchitis. Br J Dis Chest 1980; 74: 228-38
29. Sethi S, Evans N, Grant BJB, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-71
30. von Hertzen L, Alakarppa H, Koskinen R, et al. Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease. Epidemiol Infect 1997; 118: 155-64
31. Lieberman D, Ben-Yaakov M, Lazarovich Z, et al. Chlamydia pneumoniae infection in acute exacerbations of chronic obstructive pulmonary disease: Analysis of 250 hospitalizations. Eur J Clin Microbiol Infect Dis 2001; 20: 698-704
32. Blasi F, Legnani D, Lombardo VM, et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993; 6: 19-22
33. Mogulkoc N, Karakurt S, Isalska B, et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999; 160: 349-53
34. Anthonisen NR, Wright EC, Hodgkin JE, IPPB trial group. Prognosis in obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 14-20
35. Peto R, Speizer FE, Cochrane AL, et al. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease: Results from a 20 year prospective observation. Am Rev Respir Dis 1983; 128: 491-500
36. Khair OA, Devalia JL, Abdelaziz MM, et al. Effect of Haemophilus influenzae endotoxin on the synthesis of IL-6, IL-8, TNF-alpha and expression of ICAM-1. Eur Respir J 1994; 7: 2109-16
37. Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 1015-22
38. Ketterer MR, Shao JQ, Hornick DB, et al. Infection of primary human bronchial epithelial cells by Haemophilus influenzae: Macropinocytosis as a mechanism of airway epithelial cell entry. Infect Immun 1999; 67: 4161-70
39. van Schilfgaarde M, Eijk P, Regelink A, et al. Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity. Microb Pathog 1999; 26: 249-62
40. Moller LVM, Timens W, van der Bij W, et al. Haemophilus influenzae in lung explants of patients with end-stage pulmonary disease. Am J Respir Crit Care Med 1998; 157: 950-6
41. Forsgren J, Samuelson A, Ahlin A, et al. Haemophilus influenzae resides and multiplies intracellularly in human adenoid tissue as demonstrated by in situ hybridization and bacterial viability assay. Infect Immun 1994; 62: 673-9
42. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: A meta-analysis. JAMA 1995; 273: 957-60
43. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204
44. Sachs APE, Koeter GH, Groenier KH, et al. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995; 50: 758-63
45. Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: A summary and appraisal of published evidence. Ann Intern Med 2001; 134: 600-20
46. Snow V, Lascher S, Mottur-Pilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001; 134: 595-9
47. Destache CJ, Dewan N, O'Donohue WJ, et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 43: 107-13
48. Chodosh S, Schreurs A, Siami G, et al. Efficacy of oral ciprofloxacin vs clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998; 27: 730-8
49. Adams SG, Melo J, Luther M, et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345-52
50. Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalisin the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001; 32 Suppl. 2: S81-93
51. Musher DM, Bartlett JG, Doern GV. A fresh look at the definition of susceptibility of Streptococcus pneumoniae to betalactam antibiotics. Arch Intern Med 2001; 161: 2538-44
52. Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997; 112 (6 Suppl.): 310S-3S
53. Sethi S. Etiology and management of infections in chronic obstructive pulmonary disease. Clin Pulmon Med 1999; 6: 327-32
54. Sherk PA, Grossman RF. The chronic obstructive pulmonary disease exacerbation. Clin Chest Med 2000; 21: 705-21
55. Chopra I, Roberts M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65 (2): 232-60
56. Zalewska-Kaszubska J, Gorska D. Anti-inflammatory capabilities of macrolides. Pharmacol Res 2001; 44 (6): 451-4
57. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997; 156: 266-71
58. Khair OA, Devalia JL, Abdelaziz MM, et al. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J 1995; 8 (9): 1451-7
59. Zhanel GG, Dueck M, Hoban DJ, et al. Review of macrolides and ketolides: Focus on respiratory tract infections. Drugs 2001; 61 (4): 443-98
60. Scott LJ, Ormrod D, Goa KL. Cefuroxime axetil: An updated review of its use in the management of bacterial infections. Drugs 2001; 61 (10): 1455-500
61. Cohen R. Clinical efficacy of cefpodoxime in respiratory tract infection. J Antimicrob Chemother 2002; 50 (1): 23-7
62. Lamb HM, Ormrod D, Scott LJ, et al. Ceftriaxone: An update of its use in the management of community-acquired and nosocomial infections. Drugs 2002; 62 (7): 1041-89
63. Felmingham D. Review of comparative in vitro activity of some oral cephalosporins. Infect Dis Clin Pract 1998; 7 Suppl. 2: S75-80
64. Nicolau DP. Pharmacodynamic considerations in oral cephalosporin therapy: Implications for selection and effectiveness. Infect Dis Clin Pract 1998; 7 Suppl. 2: S81-2
65. Dagan R, Hoberman A, Johnson C, et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J 2001; 20: 829-37
66. Reed MD. Clinical pharmacokinetics of amoxicillin and clavulanate. Pediatr Infect Dis J 1996; 15 (10): 949-54
67. Obaji A, Sethi S. Acute exacerbations of chronic bronchitis: What role for the new fluoroquinolones? Drugs Aging 2001; 18 (1): 1-11
68. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolone: Focus on respiratory infection. Drugs 2002; 62 (6): 13-59